Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.3.14 (
ATP synthase
)
7,042
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Sulfate-reducing bacteria have been suggested to have an etiological role in the development of inflammatory bowel diseases and ulcerative colitis in humans. Traditionally. bismuth compounds have been administered to alleviate gastrointestinal
discomfort
and disease symptoms. One mechanism by which this treatment occurs is through binding bacterial derived hydrogen sulfide in the intestines. With the addition of bismuth-deferiprone, bismuth-citrate and bismuth subsalicylate to reactions containing cells of D. desulfuricans ATCC 27774, the oxidation of H
2
with sulfate as the electron acceptor was inhibited but H
2
oxidation with nitrate, nitrite and sulfite was not reduced. Our research suggests that a target for bismuth inhibition of D. desulfuricans is the F
1
subunit of the
ATP synthase
and, thus, dissimilatory sulfate reduction does not occur. At sublethal concentrations, bismuth as Bi(III) is precipitated by hydrogen sulfide produced from respiratory sulfate reduction by D. desulfuricans. Nanocrystals of bismuth sulfide were determined to be Bi
2
S
3
through the use of high resolution transmission electron microscopy imaging with X-ray energy-dispersive spectroscopy analysis. In the absence of sulfate, D. desulfuricans oxidizes H
2
with the reduction of Bi(III) to Bi
0
and this was also established by X-ray energy-dispersive spectroscopy analysis.
...
PMID:Bismuth(III) interactions with Desulfovibrio desulfuricans: inhibition of cell energetics and nanocrystal formation of Bi
2
S
3
and Bi
0
. 3154 73
